Malignant Ovarian Tumors Research Articles

Comparison of Benign, Borderline, and Malignant Ovarian Seromucinous Neoplasms on MR Imaging.

This study aimed to compare MRI findings among benign, borderline, and malignant ovarian seromucinous neoplasms. We retrospectively analyzed MRI data from 24 patients with ovarian seromucinous neoplasms-seven benign, thirteen borderline, and six malignant. The parameters evaluated included age, tumour size, morphology, number, height, apparent diffusion coefficient (ADC) values, T2 ratios, time-intensity curve (TIC) descriptors, and TIC patterns of the mural nodules. Additionally, we examined the T2 and T1 ratios of the cyst contents, tumour markers, and the presence of endometriosis. We used statistical tests, including the Kruskal-Wallis and Fisher-Freeman-Halton exact tests, to compare these parameters among the three aforementioned groups. The cases showed papillary architecture with internal branching in 57% of benign, 92% of borderline, and 17% of malignant cases. Three or fewer mural nodules were seen in 57% of benign, 8% of borderline, and 17% of malignant cases. Compared to benign and borderline tumours, mural nodules of malignant neoplasms had significantly increased height (P = 0.015 and 0.011, respectively), lower means ADC values (P = 0.003 and 0.035, respectively). The mural nodules in malignant cases also demonstrated significantly lower T2 ratios than those in the benign cases (P = 0.045). Most neoplasms displayed an intermediate-risk TIC pattern, including 80% benign, 83% borderline, and 60% malignant neoplasms, and no significant differences were observed. Most benign and borderline tumours exhibited a papillary architecture with an internal branching pattern, whereas this feature was less common in malignant neoplasms. Additionally, benign tumours had fewer mural nodules compared to borderline tumours. Malignant neoplasms were characterized by mural nodules with increased height and lower ADC values than those in benign and borderline tumours. Interestingly, all three groups predominantly exhibited an intermediate-risk TIC pattern, emphasizing the complexity of diagnosing seromucinous neoplasms using MRI.

Evaluation of cytokine immunostaining in ovarian neoplasms and endometriomas.

The objective of our study was to quantify and compare the immunostaining of IL-2, IL-5, IL-6, IL-8, and TNF-α in endometriomal tissue, non-neoplastic tumors, benign neoplasms, and malignant ovarian neoplasms. The study involved 90 patients: 15 non-neoplastic ovarian lesions, 28 ovarian benign neoplasms, 28 ovarian malignant neoplasms, and 19 ovarian endometriomas were diagnosed. Immunohistochemistry was performed for cytokines IL-2, IL-5, IL-6, IL-8, and TNF-α and their concentrations were compared in these groups. Fisher's exact test was used, requiring a P-value of < 0.05 for significance. IL-5 and IL-8 epithelial immunostaining is stronger in endometriomas than in ovarian cancer (P-values of 0.0046 and 0.0149, resp.). The stromal immunostaining of TNF-α, IL-5, IL-6, and IL8 is stronger in endometriomas than in ovarian cancer (P-values of 0.0008, < 0.0001, 0.0003, and 0.0006, resp.). Stronger immunostaining of some cytokines in endometriomas compared to ovarian cancer reflects an inflammatory and immune response that could be future targets for new discoveries about the infiltrative behavior of endometriosis.

Expression and Clinical Progress of Tumor Markers CA125, CA199, HE4 and HCG in Ovarian Malignant Tumors

Expression and Clinical Progress of Tumor Markers CA125, CA199, HE4 and HCG in Ovarian Malignant Tumors

Ovarian Yolk Sac Tumors: Is Fertility Preservation Possible?

Abstract Yolk sac tumors make up 14% to 20% of all malignant ovarian germ cell tumors. Serum alpha-fetoprotein (AFP) levels are elevated in a significant number of patients and are useful for monitoring the response to treatment and for post-treatment surveillance. Surgery is required for diagnosis, staging, and treatment. The first case is a 12-year-old girl presented with abdominal pain. The ultrasonography (US) showed a huge pelvic tumor. AFP level was high (1000 mg/ml). Right salpingo-oophorectomy and pelvic lymphadenectomy were done. Histopathology reported yolk sac tumor of ovary. She received 3 courses of bleomycin, etoposide, cisplatin (BEP). The second case is a 25-year-old G1AB1 presented with pelvic pain and distension. The US showed a huge pelvic tumor in the right abdominopelvic region. AFP level was high (1000 mg/ml). Right salpingo-oophorectomy, omentectomy, and appendectomy were done. Histopathology reported yolk sac tumor of ovary. The patient received four cycles of BEP protocol; AFP level decreased to 10 mg/ml after the four cycles of chemotherapy. The third case is a 21-year-old girl presented with abdominal pain. The US showed a huge pelvic tumor in the right adnexa. AFP level was high (8700 mg/ml). Right salpingo-oophorectomy and pelvic lymphadenectomy were done. Yolk sac tumor is rare in children and it could be cured usually. In this study, we described three patients with ovarian yolk sac tumors and their fertility preservation treatments.These cases has reminded that in young age with high AFP levels and rapidly growing ovarian mass, diagnosis of the yolk sac tumor has to be kept in mind.

Decision-Level Fusion Classification of Ovarian CT Benign and Malignant Tumors Based on Radiomics and Deep Learning of Dual Views

Decision-Level Fusion Classification of Ovarian CT Benign and Malignant Tumors Based on Radiomics and Deep Learning of Dual Views

Histopathological Spectrum of Ovarian Tumours in a Tertiary Care Centre in South Kerala, India: A Cross-sectional Study

Introduction: Ovarian tumours are among the most common tumours in females, exhibiting diverse histopathological patterns that remain crucial for early diagnosis. Proper classification of ovarian neoplasms, particularly malignant ones, is essential for accurate treatment. Accurately subclassifying ovarian tumours aids in treatments such as targeted therapy. Aim: To examine the histopathological spectrum of ovarian tumours and to assess the role of histopathology in accurate diagnosis and treatment. Materials and Methods: A cross-sectional study on the histopathological spectrum of ovarian tumours was conducted in Department of Pathology, Travancore Medical College, Kollam, Kerala, India, over a five-year period (January 2017 to December 2021). The study included 850 ovarian specimens, and the various histopathological patterns were studied according to the World Health Organisation (WHO) classification of ovarian tumours, 5th edition, 2020. These patterns and age distribution were expressed in frequency and percentage. Results: Out of the 850 ovarian specimens, 140 were neoplastic and 710 were non neoplastic. Abdominal pain was the most common clinical presentation (30%). Among the 140 neoplastic cases, 115 were benign, 20 were malignant, and five were borderline. The majority of cases, including benign, borderline, and malignant tumours, were seen in the age group of 31-40 years (25.71%). Benign tumours were more common than malignant ones in all age groups. Categorising based on histopathological patterns, epithelial tumours were the most common (88 cases, 62.86%). Serous cystadenoma was the most common benign tumour, constituting 36 out of 115 benign cases (25.71%). Borderline serous tumour was the most common borderline epithelial tumour (3 out of total 5 borderline ovarian neoplasms, 2.14%). Serous cystadenocarcinoma was the most common malignant tumour (5 cases, 03.57%). Conclusion: The wide spectrum of ovarian tumours presents diagnostic challenges. Effective therapeutic management of ovarian malignant tumours continues to be a challenge for clinicians. Histopathological examination remains crucial in diagnosis. Accurate histopathological diagnosis, combined with clinical staging, facilitates prompt and appropriate treatment and timely patient management.

Mean platelet volume as a prognostic factor in ovarian lesions

Even nowadays the diagnostic of ovarian cancer is difficult to be established preoperatively, and therefore a significant number of patients are submitted to a too extensive or to an incomplete surgical procedure. Therefore attention was focused on identifying more reliable markers which might help the clinician to distinguish between benign and malignant ovarian lesions. The aim of the current paper is to analyze the differences between benign and malignant ovarian tumors based on the preoperative levels of the mean platelet volume.

Features of diagnosing ovarian tumors in women of pre- and postmenopausal age

Currently, one of the main ways to fight cancer, which can improve the results of treatment of ovarian neoplasms, is screening. Presently, the issue of organizing and conducting preventive examinations of women, including those of reproductive age, is one of the most urgent problems of primary health care institutions. The subjects of the study were 168 pre- and postmenopausal patients aged 20 to 60 years with ovarian tumors suspected of oncological pathology, who received treatment on the basis of the Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology for the period from 2018 to 2022, taking into account the selected age interval. An assessment was made of laboratory research methods, such as: general blood count, biochemical blood test, general urinalysis, tumor-associated marker CA-125, HE-4. In the comparative analysis of risk factors, when ovarian tumors develop in pre- and postmenopausal women, malignant and borderline ovarian tumors have complaints, parity, gynecological anamnesis, and the presence of extragenital diseases, which do not have specific characteristics for malignant or borderline tumors. therefore, it does not provide sufficient information in the process of diagnosing ovarian tumors. The sonographic characteristics associated with the degree of ovarian tumor malignancy were examined, and the tumor had a solid component (p <0.001), the presence of obstructions (p = 0.0005), and the presence of growth on the inner surface of the capsule (p <0.001), the presence of a significant amount of free fluid in the pelvic cavity (p <0.001), the roughness of the surface of the tumor capsule (p < 0.001) were observed to be characteristic of more dangerous processes.

Clinicopathological characteristics and prognosis in ovarian metastatic tumors from non-gynecologic primary sites

Clinicopathological characteristics and prognosis in ovarian metastatic tumors from non-gynecologic primary sites

Differential ultrasound diagnosis of benign and malignant ovarian tumors: diagnostic models, algorithms, stratification systems, consensuses (1990–2023).

The review presents the most common diagnostic models, algorithms and stratification systems developed for the purpose of optimal differential diagnosis of benign and malignant ovarian tumors from 1990 to the present. Four variants of the RMI 1–4 malignancy risk index with their comparative characteristics are described. A proprietary comprehensive ultrasound scoring scale for ovarian tumors is described. Algorithms for the integrated use of echography and tumor markers (CA-125, HE4, ROMA), including the Risk Ovarian Cancer computer system, are presented. All existing IOTA diagnostic models are described: Simple IOTA rules, Simple IOTA rules with quantitative calculation of the risk of malignancy, Logistic regression analysis IOTA LR1 & LR2, Easy IOTA descriptors, IOTA ADNEX. The main algorithms for the integrated use of IOTA models are presented. The principles of using the diagnostic stratification systems GI-RADS and O-RADS are outlined. Clinical examples of the use of diagnostic models are given. The review concludes by presenting the ESGO/ISUOG/IOTA/ESGE consensus on the preoperative diagnosis of ovarian tumors.

Differential diagnosis of primary and metastatic ovarian carcinomas

Ovarian tumors constitute 3.4 % of the structure of oncological diseases in women worldwide. However, the ovaries are also a common target for metastasis of carcinoma from other organs. Conducting differential diagnosis between primary carcinoma and metastasis is often challenging. The aim of this study is to highlight the issues of morphological and immunohistochemical differential diagnosis of primary ovarian carcinomas and metastases from carcinomas of various organs to the ovaries. Materials and methods. Data analysis of clinical and pathohistological studies of 381 patients. Paraffin sections for pathohistological studies were stained with hematoxylin and eosin using standard methodology. Immunohistochemical studies were conducted in 161 cases using a panel of antibodies: cytokeratins, estrogen receptors, progesterone receptors, CA125, TTF1, Vimentin, CDX2, Villin, Chromogranin A, Synaptophysin, CD56, GATA, p53, Inhibin A, FOXL-2, PAX-8, Ki-67. The specimens were examined and analyzed using the Axioskop 40 microscope (Zeiss) with the AxioCam MRc camera (Zeiss). Results. The article discusses key issues of differential diagnosis of primary and metastatic ovarian carcinomas based on a large clinical and operational material. The application of an adequate panel of immunohistochemical antibodies for verification is considered. The results of the frequency of occurrence of different histological variants of ovarian carcinomas and metastases to the ovaries from carcinomas of other organs are provided based on our own research from 2019 to 2023. The main morphological and immunohistochemical indicators for practical use in the work of a pathologist in the verification of ovarian tumors are presented. An example of forming an antibody panel, taking into account clinical and morphological indicators in a specific clinical case from our own practice, is given. Conclusions. Metastases of carcinomas from other organs to the ovaries constitute half of all cases requiring immunohistochemical investigation based on morphological structure. The most common are metastases from breast and colorectal cancers. However, the diagnosis of metastatic intestinal carcinoma is particularly challenging, as there is usually no clear clinical picture. In the differential diagnosis of primary and metastatic ovarian tumors, a comprehensive approach to analyzing the clinical presentation, microscopic structure of the tumor, and the surrounding tissue plays a significant role. Additionally, the formation of an antibody panel, taking into account these data, is crucial. The article provides a list of antibodies that have demonstrated greater effectiveness in our work.

Diagnostic value of a CT-based radiomics nomogram for discrimination of benign and early stage malignant ovarian tumors

BackgroundThis study aimed to identify the diagnostic value of models constructed using computed tomography-based radiomics features for discrimination of benign and early stage malignant ovarian tumors.MethodsThe imaging and clinicopathological data of 197 cases of benign and early stage malignant ovarian tumors (FIGO stage I/II), were retrospectively analyzed. The patients were randomly assigned into training data set and validation data set. Radiomics features were extracted from images of plain computed tomography scan and contrast-enhanced computed tomography scan, were then screened in the training data set, and a radiomics model was constructed. Multivariate logistic regression analysis was used to construct a radiomic nomogram, containing the traditional diagnostic model and the radiomics model. Moreover, the decision curve analysis was used to assess the clinical application value of the radiomics nomogram.ResultsSix textural features with the greatest diagnostic efficiency were finally screened. The value of the area under the receiver operating characteristic curve showed that the radiomics nomogram was superior to the traditional diagnostic model and the radiomics model (P < 0.05) in the training data set. In the validation data set, the radiomics nomogram was superior to the traditional diagnostic model (P < 0.05), but there was no statistically significant difference compared to the radiomics model (P > 0.05). The calibration curve and the Hosmer–Lemeshow test revealed that the three models all had a great degree of fit (All P > 0.05). The results of decision curve analysis indicated that utilization of the radiomics nomogram to distinguish benign and early stage malignant ovarian tumors had a greater clinical application value when the risk threshold was 0.4–1.0.ConclusionsThe computed tomography-based radiomics nomogram could be a non-invasive and reliable imaging method to discriminate benign and early stage malignant ovarian tumors.

A virtual consultation system for very rare tumors in children and adolescents – an initiative of the European Cooperative Study Group in Rare Tumors in Children (EXPeRT)

BackgroundVery rare tumors (VRTs) in children and adolescents are orphan diseases defined by an annual incidence of <2/1000,000. For a long time, VRTs have been outside of clinical and research groups in the field of pediatric oncology. As a result, exchange of experience and development of therapeutic standards have not been promoted. After the foundation of several national VRT working groups and the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT), a virtual consultation system (VCS) has been established, which specifically aimed at facilitating access to clinical consultation in complicated cases of VRTs. MethodsThe VCS has been open to physicians. After initial registration, they can present VRT patients free of charge. Patient consent and data pseudonymization were mandatory. Within the VCS, disease specific interdisciplinary panel discussions with at least three experts from the EXPeRT group and partners have been opened, and at the end of the discussion, a written summary and recommendation was provided. ResultsBetween Mai 2017 and March 2023, 160 cases from 27 countries (20 European, 7 non-European) have been discussed in the VCS. The most common diagnoses were adrenocortical carcinoma, malignant skin tumors and malignant ovarian tumors. In a survey three months after panel discussion, more than 90% of requesting physicians evaluated the VCS to be easy to use, helpful and to have a significant impact on patient management. ConclusionA VCS may provide significant assistance in the management of children and adolescents with VRTs. Furthermore, it may help to overcome inequalities in access to adequate treatment in countries with lower health care system resources or without established VRT study groups. Therefore, EXPeRT will continue to support the VCS. For this purpose, the VRT panels have been integrated into the Clinical Patient Management System (CPMS) within the European Reference Network Initiative (ERN PAedCan).

Prospective use of O-RADS and ADNEX ultrasound systems for risk stratification of ovarian malignancies

Objectives. A prospective study of the diagnostic value of ultrasound ovarian cancer risk stratification systems ADNEX and O-RADS in the differential diagnosis of benign and malignant ovarian tumors.Material and methods. 59 patients with 43 benign and 25 with malignant ovarian tumors were prospectively examined. The ultrasound diagnostic systems IOTA ADNEX (installed on the device) and O-RADS (ACR Guidance smartphone application) were used to assess the risk of ovarian cancer. An ultrasound report on the presence of a malignant tumor with appropriate routing of the patient was given when the risk of malignancy according to ADNEX was ≥10%, as well as when the risk of malignancy was ≥4 points according to O-RADS. All patients underwent surgical treatment at the Regional Clinical Hospital (Vladimir) and the Regional Clinical Oncology Hospital (Vladimir).Results. Sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and area under the curve (AUC) were respectively for ADNEX: 96, 81, 75, 97 and 87%, AUC 0.933; for O-RADS: 100, 74, 69, 10% and 90%, AUC 0.926.Conclusion. Both ultrasound diagnostic systems demonstrated very high sensitivity in the prospective differential diagnosis of benign and malignant ovarian tumors. At the same time, O-RADS made it possible to make the correct diagnosis in all 25 cases of malignant tumors. At the same time, both systems showed low specificity, with ADNEX having a slightly higher specificity (p &gt; 0.05). AUC values were high for both diagnostic systems. In connection with the results of the study, we currently consider it advisable to simultaneously use the ADNEX and O-RADS systems for ultrasound examination in gynecology, reflecting the results of calculating the risk of malignant neoplasms of the adnexal mass in the ultrasound examination protocol

Impact of COVID-19 on gynecological cancer incidence: a large cohort study in Japan.

The influence of the coronavirus disease 2019 (COVID-19) pandemic on the number of newly diagnosed gynecological cancers has not been extensively investigated in Japan. This study determined the impact of COVID-19 on the incidence of gynecological cancer. Using the Japanese Society of Obstetricians and Gynecologic Oncology registry database, the distribution of the number of patients based on clinical staging or tumor-node-metastasis classifications before and during the COVID-19 pandemic was analyzed to compare the trends. The clinical staging classification of cervical cancer in Japan was based on the International Federation of Gynecology and Obstetrics (FIGO) 2008 from 2018 to 2020 and on the FIGO 2018 from 2021. Since FIGO-2018 classified N1 cases as stage IIIC, we focused on T classification without referencing the clinical staging (FIGO staging) of patients with cervical cancer in 2021. The number of patients with endometrial cancer and malignant ovarian tumors of all clinical stages increased uniformly yearly, while that of those with stage III cervical cancer rapidly increased in 2021 owing to the adoption of the revised classification. On comparing cases of cervical cancer in 2020 and 2021, we found that T1 cases decreased and T2 and T3 cases increased in 2021 compared to those in 2020 (p = 0.006). Cervical intraepithelial neoplasia/adenocarcinoma in situ incidence decreased in 2020 compared to that in 2019 but increased again in 2021. The number of patients with cervical cancer decreased in most prefectures in 2020. The incidence of locally advanced cervical cancer increased during the COVID-19 pandemic.

D-dimer, Fibrinogen and Tumor Marker Levels in Patients with benign and Malignant Ovarian Tumors.

Limited studies have investigated the differences between the levels of plasma coagulants and tumor markers in ovarian cancer. Therefore, we conducted this study to determine and compare the level of coagulation, fibrinolysis and tumor markers in patients with benign and malignant ovarian tumors. This cross-sectional study was conducted between January 2022 and February 2023 in Imam Hossein Hospital on patients with ovarian mass. Laboratory tests included platelet count, PT, INR, PTT, fibrinogen and D-dimer were sent to the pathology laboratory to be examined by a pathologist. Based on histopathology, patients were divided into benign, borderline and malignant groups. Logistic regression was used for determine predictors of malignancy. Receiver operating characteristics (ROC) curves and their corresponding 95% CI were determined for the predictor value of the full model. From 141 investigated patients, tumor type in 124 (87.94%) patients were benign, in 12 (8.51%) was malignant and in 5 (3.55%) was borderline. D-dimer, Ca-125 and HE4 were significantly higher in the patients with malignant tumor type (P<0.001), whereas AFP was significantly higher in patients with borderline tumor type (P<0.001). With one-unit increase in D-dimer odds of borderline/malignant tumor 0.3% increases (OR=1.003, 95% CI: 1.001, 1.006) and with one-unit increase in Ca-125 odds of borderline/malignant tumor 1% increases (OR=1.01, 95% CI: 1.003, 1.02). We found that plasma fibrinogen, D-dimer and Ca-125 levels are independently associated with malignant ovarian tumors and combined use of these markers has the high discriminant power for distinction of benign and malignant ovarian masses.<br />.

Preoperative Serum Vascular Endothelial Growth Factor as a predictor of malignant ovarian tumor

Background: Effective biomarkers for accurate characterization of newly diagnosed ovarian tumors and adnexal masses are of paramount importance. The availability of an ideal serum marker is highly recommended. Vascular endothelial growth factor (VEGF) may be considered as a predictor of ovarian cancer. Objective: This study explored the efficacy of preoperative serum VEGF for detection of malignant ovarian tumor. Methods: This cross sectional analytical study was conducted among 86 patients who were enrolled for this study according to final histopathology report and who did not receive any kind of treatment. Serum levels of VEGF-A were determined by using ELISA method. ROC curve was plotted to achieve the best cutoff value of serum VEGF. The Mann-Whitney test was used to compare the VEGF distribution across sub-groups of patients. Result: A statistically significant difference in the levels of serum VEGF level was observed between benign and malignant ovarian tumor patients. Ovarian cancer patients had a higher preoperative median S. VEGF level of 753.8 pg/ml than that of benign ovarian masses (median 241.8 pg/ml; p value 0.001). The ability of serum VEGF to differentiate malignancy from benign masses at a cut-off value of 547.85 pg/ml gave a sensitivity of 90.1%, a specificity of 93.5%. Conclusion: This study revealed that preoperative serum VEGF may be used as a feasible vascular marker and predictor of malignant ovarian tumors. Bangladesh Med Res Counc Bull 2023; 49: 183-189

Effectiveness and safety of nintedanib in prevention of pulmonary fibrosis induced by bleomycin in malignant ovarian germ cell tumour: study protocol for a randomised, double-blind, placebo-controlled trial

IntroductionBleomycin is a crucial and irreplaceable chemotherapy regimen for malignant ovarian germ cell tumours (MOGCTs) but its toxicities especially pulmonary fibrosis have limited the dose of treatment efficacy and decreased...

Clinical Presentation and Histological Types of Ovarian Tumor in Patients Admitted in Tertiary Care Center

Background: Ovarian cancer is the eighth most frequent cancer among women worldwide, accounting for 4% of all cancers in the female population. When compared to other reproductive system cancers, ovarian cancer has a high death and morbidity rate. Objectives: The aim of the study was to assess the clinical presentation and histological types of ovarian tumor in patients admitted in tertiary care center. Methods: A descriptive cross-sectional study was conducted to determine the clinical presentation and histopathological types of ovarian tumour diagnosed at Medical college for women, Uttara and Nightingale medical college, Ashulia. The study was approved by the Institutional Review Board (IRB) and 600 patients diagnosed with ovarian tumors were consecutively included in the study from July 2009 to August 2016. The cases were diagnosed and subclassified in accordance with the WHO Classification of Female Genital Tumours, Fourth Edition. Statistical Package for Social Sciences (SPSS) application, version 25, was used for data analysis. Results: Out of Total Gynaecological admission of 4800 patients during the study period, 600 patients were admitted with diagnosis of ovarian Tumor, So occurance was 12.5%. the mean age of the patients was 35 ± 2.09. About 8.6% of the patients had less than 20 years old. 56.6% were within the age group of 21-40, 29.8% were within the age group of 41-60 and only 5% had more than 60 years. The mean Menarche in years was 14.6 ± 1.02 and Menopause in years was 48.7 ± 2.46. Regarding clinical presentation 37.40% had abdominal pain, 55.50% had abdominal mass, 3% had abdominal distension,2% had ascites, 0.50% had menstrual irregularities and 2.50% were asymptomatic. Regarding surgical procedure, 35% undergone Total abdominal hysterectomy and bilateral salpingo-oophorectomy, 18.33% Bilateral salpingo-oophorectomy, 15% Right salpingo-oophorectomy and Left salpingo-oophorectomy recommendation, 13.33% Right cystectomy, 3.33% Left cystectomy. Regarding consistency of tumour 57.33% were cystic, 37% were solid, 5.33% were complex and 0.33% were Diffuse pattern (metastatic tumor). Benign tumors were 77%, borderline 16.67% and malignant 6.33% cases. Out of 462 benign tumors, Serous cystadenoma (230/49.78%), Mucinous cystadenoma (60/12.98%), benign Brenner tumor (10/2.16%), Mature cystic teratoma (110/23.80%), stroma ovarii (10/2.16%), Fibroma (10/2.16%), Fibro-thecoma (12/ 2.59%), leiomyoma (20/4.34%). Out of 38 malignant tumour, Serous cystadenocarcinoma (11/28.94%), mucinous cystadenocarcinoma (6/15.78%), clear cell carcinoma (1/2.63%), Malignant Brenner tumor (1/2.63%), endometroid adenocarcinoma (4/10.52%), squamous cell carcinoma arising in mature teratoma (1/2.63%), Dysgerminoma (7/18.4%), Immature teratoma (1/2.63%), malignant mixed germ cell tumor (1/2.63%), Adult granulosa cell tumor (4/10.52%), Krukenburg tumor (1/2.63%). Survival status was satisfactory; 99.67% patients was alive. Conclusion: The study found that ovarian neoplasms had ambiguous signs and symptoms, were mostly seen in reproductive age groups, and were mostly benign. The proportion of malignant ovarian neoplasms was significantly lower than that of benign ovarian neoplasms. Although incidence of malignant tumor is less common but gynocologists should be more careful in diagnosis of malignancy as ovaries are pelvic organs and definite screening methods are not available and malignancy can occur in any age.

Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements

The purpose of the study was to systematize and summarize the literature data on the study of clinical and genetic aspects, molecular pathogenesis, as well as new trends in the diagnosis and treatment of ovarian cancer.Material and Methods. A literature search was conducted using Web of science, scopus, medline, pubmed, and elibrary databases.Results. Ovarian cancer is the leading cause of death in women diagnosed with gynecological cancer. ovarian cancer is a heterogeneous disease composed of different types of tumors, each of which has differences in pathogenesis, spectrum and mutation frequencies in characteristic genes, response to therapy and prognosis of the disease. more than 80 % of all malignant ovarian tumors are of epithelial origin (carcinomas) and about 26 % of all cases of ovarian cancer are caused by germline mutations found in the BRCA1/BRCA2 genes. to date, the priority areas in the study of ovarian cancer are the improvement of diagnostic methods, algorithm of examination of women, identification of new biomarkers, study of tumor microenvironment and composition of ascitic fluid to detect cancer at early stages and prescribe appropriate therapy. Recent advances in targeted therapy based on the molecular profile of the tumor have made it possible to personalize treatment and increase its effectiveness. Achievements in molecular genetic, cytological, immunological and biochemical studies contribute to the development of novel approaches to the diagnosis and treatment of ovarian cancer.Conclusion. With the advent of new novel approaches to the diagnosis and treatment of ovarian cancer, it is becoming increasingly clear that the tumor microenvironment can significantly affect the success of chemotherapy. New biomarkers can help identify the best candidates for ovarian cancer treatment. Further basic and applied research is needed to explore the use of different diagnostic and therapeutic agents in ovarian cancer.